Arkansas Children's provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties for 2024-2025.
Our ERs are staffed 24/7 with doctors, nurses and staff who know kids best – all trained to deliver right-sized care for your child in a safe environment.
Arkansas Children's provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties for 2024-2025.
When you give to Arkansas Children's, you help deliver on our promise of a better today and a healthier tomorrow for the children of Arkansas and beyond
When you give to Arkansas Children’s, you help deliver on our promise of a better today and a healthier tomorrow for the children of Arkansas and beyond.
This study will evaluate the use of Difluoromethylornithine (DFMO) as a single agent in patients with high risk medulloblastoma after completing therapy as maintenance therapy with the hopes of preventing relapse.
The purpose of this study is to provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG) and collect sufficient information about the patient’s treatment.
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
A prospective open label, multicenter study to evaluate the feasibility and side effects of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
The purpose of this study is to find out what effects study treatment with talazoparib in combination with conventional chemotherapy agents topotecan and gemcitabine has on you and your cancer.
We are looking for children between the ages of 3 and 10 to help us learn about typical brain development. Learn more about the Unitcall clinical trial.
Español 
Cookie Settings 
Accessibility